FiercePharmaNovo Nordisk lands back in Sanders' crosshairs, this time over steep costs of Ozempic and Wegovy10 hours agoFraiser KansteinerBy Fraiser Kansteinermore_vert
The New York TimesInside Novo Nordisk, the Company Behind Ozempic and Wegovy6 days agoEshe Nelson and Charlotte De La FuenteBy Eshe Nelson and Charlotte De La Fuentemore_vert
CNBCNovo Nordisk's $1,000 diabetes drug Ozempic can be made for less than $5 a month, study suggests27 MarAnnika Kim ConstantinoBy Annika Kim Constantinomore_vert
FortuneOzempic maker Novo Nordisk facing pressure as study finds $1000 appetite suppressant can be made for just $528 MarRobert Langreth and Madison MullerBy Robert Langreth and Madison Mullermore_vert
Reuters.comFDA approves Novo Nordisk's Wegovy for lowering heart risks8 MarSriparna Roy and Patrick WingroveBy Sriparna Roy and Patrick Wingrovemore_vert
Barron'sNovo Nordisk, ASML, and Other Magnificent 18 Stocks for Europe17 days agoAdam ClarkBy Adam Clarkmore_vert
The Motley FoolIs Novo Nordisk the Best Healthcare Stock for You?31 MarDavid JagielskiBy David Jagielskimore_vert
POLITICO EuropeThe Ozempic boom: How the entire country of Denmark became a company town26 MarCharlie DuxburyBy Charlie Duxburymore_vert
ForbesHere's Why Ozempic And Mounjaro Rivals Won't Topple Drugmakers Novo Nordisk And Eli Lilly Anytime Soon27 MarRobert HartBy Robert Hartmore_vert
Reuters.comUS Senate committee investigates pricing of Novo's Ozempic and Wegovy2 days agoPratik Jain, Shounak Dasgupta and Christy SanthoshBy Pratik Jain, Shounak Dasgupta and Christy Santhoshmore_vert
Yahoo FinanceZacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie16 hours agomore_vert
Pharmaceutical TechnologySanders takes aim at US drug prices of Novo’s Ozempic and Wegovy9 hours agoJustine RaBy Justine Ramore_vert
STATNovo Nordisk to discontinue Levemir, insulin patients left hanging2 days agoElaine ChenBy Elaine Chenmore_vert
BioSpaceBiopharma Layoff Tracker 2024: BMS, CureVac, Tessera and More Cut Staff2 hours agoNeil VerselBy Neil Verselmore_vert
CNBCSenate launches investigation into high prices of Ozempic and Wegovy in the U.S.2 days agoRyan AnastasioBy Ryan Anastasiomore_vert
NBC NewsHow one state is trying to make weight loss drugs cheaper2 days agoBerkeley Lovelace, Jason Kane and Erin McLaughlinBy Berkeley Lovelace, Jason Kane and Erin McLaughlinmore_vert
The New York TimesSenate Begins Investigation Into Ozempic and Wegovy Prices2 days agoDani BlumBy Dani Blummore_vert
Yahoo FinanceWhy Novo Nordisk Topped the Market Today4 days agoEric T VolkmanBy Eric T Volkmanmore_vert
STATReadout newsletter: Obesity drug spending, Novo Nordisk and insulin2 days agoElaine ChenBy Elaine Chenmore_vert
BioSpaceSanders Launches Probe of ‘Outrageously High Prices’ of Novo’s Ozempic, Wegovy17 hours agoTristan ManalacBy Tristan Manalacmore_vert
Reuters.comMedicare beneficiaries could be eligible for Wegovy coverage, study shows2 days agomore_vert
STATReadout Newsletter: Novo Nordisk, antibiotics, Duchenne - STAT4 days agoMeghana KeshavanBy Meghana Keshavanmore_vert
QuartzSanders launches Senate investigation of high prices for Ozempic, Wegovy18 hours agoBruce GilBy Bruce Gilmore_vert
European Pharmaceutical ReviewNovo Nordisk to buy Cardior Pharmaceuticals25 MarCaroline PeacheyBy Caroline Peacheymore_vert
FiercePharmaNovo Nordisk attracts lawmakers' ire for Levemir insulin pull8 days agoFraiser KansteinerBy Fraiser Kansteinermore_vert
Pharmaceutical ExecutiveLene Oddershede Discusses Upcoming Projects from the Novo Nordisk Foundation7 days agoDon TracyBy Don Tracymore_vert
CNNSanders launches Senate investigation into ‘outrageously high’ pricing of Ozempic, Wegovy2 days agoKatherine Dillinger and Tami LuhbyBy Katherine Dillinger and Tami Luhbymore_vert
EuronewsDrugmaker Novo Nordisk reaches market value of $500 million31 JanDoloresz KatanichBy Doloresz Katanichmore_vert
The New York TimesInside Novo Nordisk’s Headquarters6 days agoEshe Nelson and Nikolay NikolovBy Eshe Nelson and Nikolay Nikolovmore_vert
CNBCMore than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says2 days agoAnnika Kim ConstantinoBy Annika Kim Constantinomore_vert
Reuters.comNovo Nordisk strikes deal worth up to $1.1 bln to expand cardio business25 MarStine Buch JacobsenBy Stine Buch Jacobsenmore_vert
CNBCNovo Nordisk CEO says experimental weight loss pill could become a best-in-class drug8 MarAnnika Kim ConstantinoBy Annika Kim Constantinomore_vert
Pharmaceutical ExecutiveNovo Nordisk Foundation Executive Talks Biomedical Quantum Sensing9 days agoDon TracyBy Don Tracymore_vert
BloombergWegovy Medicare Coverage Expands to Millions With Heart Disease2 days agoJessica NixBy Jessica Nixmore_vert
European Pharmaceutical ReviewNovo Nordisk $11b acquisition to support manufacturing capacity5 Febmore_vert
EuronewsNovo Nordisk crossroads: Can the pharma giant address the supply woes?10 FebPiero CingariBy Piero Cingarimore_vert
Reuters.comNovo Nordisk-owner to expand in India this year12 MarJacob GronholtBy Jacob Gronholtmore_vert
BloombergNovo Nordisk (NOVOB) Earnings Surge on Wegovy Frenzy31 JanKit Rees and Naomi KresgeBy Kit Rees and Naomi Kresgemore_vert
Reuters.comNovo Nordisk parent refiles US application on Catalent deal18 days agoJacob Gronholt, Anna Ringstrom and Stine Buch JacobsenBy Jacob Gronholt, Anna Ringstrom and Stine Buch Jacobsenmore_vert
The New York TimesHow Ozempic Is Transforming a Small Danish Town6 days agoEshe NelsonBy Eshe Nelsonmore_vert
Investor's Business DailyWeight Loss Leader Hits Buy Trigger In Market Rebound2 days agoScott LehtonenBy Scott Lehtonenmore_vert
USA TODAYWegovy, Ozempic cost a pretty penny. Many employers don't want to pay16 hours agoKen AlltuckerBy Ken Alltuckermore_vert
McDuffie ProgressSanders Launches Senate Investigation into Sky-High Ozempic and Wegovy Drug Prices9 hours agomore_vert
UNHCRNovo Nordisk Foundation and Grundfos Foundation partner with UNHCR to strengthen inclusive health care for ...11 Decmore_vert
Pharmaceutical TechnologyNovo Nordisk signs $1.46bn deal to develop molecular glue therapies27 FebPhalguni DeswalBy Phalguni Deswalmore_vert
Financial TimesNovo Nordisk strikes $11bn deal to expand production of weight loss drug5 Febmore_vert
FortuneNovo Nordisk Foundation to build Nvidia-backed AI supercomputer20 MarChris Morris and Prarthana PrakashBy Chris Morris and Prarthana Prakashmore_vert
Le Monde Danish pharmaceutical giant Novo Nordisk boosted by its anti-obesity medication10 MarZeliha ChaffinBy Zeliha Chaffinmore_vert
CNBCWeight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that10 FebAnnika Kim ConstantinoBy Annika Kim Constantinomore_vert
The Motley FoolMissed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.2 days agoKeith SpeightsBy Keith Speightsmore_vert
InvestopediaWegovy Maker Novo Nordisk Stock Surges on Promising Trial of Obesity Pill Amycretin7 MarFatima AttarwalaBy Fatima Attarwalamore_vert
Pharmaceutical ExecutiveNovo Nordisk Foundation's SVP of Natural & Technical Sciences Discusses the Future of Quantum Sensing in Clinical ...8 days agoDon TracyBy Don Tracymore_vert
The HillSanders launches investigation into ‘unacceptable’ diabetes, weight loss drug prices2 days agoSarah FortinskyBy Sarah Fortinskymore_vert
Reuters.comDanish central bank raises 2024 GDP forecast on Novo Nordisk, gas field restart20 MarJacob Gronholt, Stine Buch Jacobsen and Miral FahmyBy Jacob Gronholt, Stine Buch Jacobsen and Miral Fahmymore_vert
Financial TimesNovo Nordisk chief seeks more deals to cement weight-loss lead amid 'hype'8 Marmore_vert
Labiotech.euAmycretin: Novo Nordisk's new rival to Wegovy in obesity treatment27 MarWillow Shah-nevilleBy Willow Shah-nevillemore_vert
The Washington PostNovo Nordisk profit surges as it boosts supplies of Wegovy31 JanDaniel GilbertBy Daniel Gilbertmore_vert
FortuneOzempic-maker Novo Nordisk fuels Denmark GDP per capita growth27 FebPeter Vanham and Nicholas GordonBy Peter Vanham and Nicholas Gordonmore_vert
InvestopediaNovo Nordisk Stock Hits Record High as Wegovy Maker Sees Up To 26% Sales Growth This Year31 JanNisha GopalanBy Nisha Gopalanmore_vert
FiercePharmaRiding GLP-1 wave, Novo Nordisk lays out $560M to boost drug production in China19 MarFraiser KansteinerBy Fraiser Kansteinermore_vert
Pharmaceutical TechnologyNovo Nordisk acquires Alkermes's Irish plant to expand manufacturing capacity14 DecPhalguni DeswalBy Phalguni Deswalmore_vert
The GuardianObesity drug boom pushes Novo Nordisk shares to record high31 JanJulia KolleweBy Julia Kollewemore_vert
Fast CompanyNovo Nordisk's weight-loss wonder drugs could also help with dementia, liver disease, and more19 MarAdam BluesteinBy Adam Bluesteinmore_vert
ForbesOzempic Maker Novo Nordisk Beats Profit Forecasts As Weight-Loss Sales Soar31 JanRobert HartBy Robert Hartmore_vert
Clinical Trials ArenaNovo Nordisk's semaglutide cuts kidney disease progression in trial6 Marmore_vert
Common DreamsSanders Launches Probe of 'Outrageously Overpriced' Ozempic and Wegovy2 days agoBrett WilkinsBy Brett Wilkinsmore_vert
ForbesBernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy27 MarSara DornBy Sara Dornmore_vert
Reuters.comEli Lilly, Novo Nordisk get growth stock status on weight-loss drug boost16 FebMedha Singh and Manas MishraBy Medha Singh and Manas Mishramore_vert
Financial TimesFT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk18 DecHannah KuchlerBy Hannah Kuchlermore_vert
InvestopediaNovo Nordisk Buys Heart Disease Drug Maker Cardior in $1.11 Billion Deal25 MarAaron McDadeBy Aaron McDademore_vert
FortuneOzempic maker Novo Nordisk has a new goal for its leadership team: Make sure no more than 10% of your staff are ...22 MarOrianna Rosa RoyleBy Orianna Rosa Roylemore_vert
Built InRevolutionizing Drug Development: Novo Nordisk’s AI-Powered Future21 days agoBrigid HoganBy Brigid Hoganmore_vert
European Pharmaceutical ReviewNovo Nordisk plans multi-billion Denmark manufacturing expansion10 Novmore_vert
CNBCNovo Nordisk market cap surpasses Tesla on new obesity pill trial data8 MarKaren GilchristBy Karen Gilchristmore_vert
CNBCNovo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverage8 MarAnnika Kim ConstantinoBy Annika Kim Constantinomore_vert
CNBCNovo Nordisk shares jump 8% on promising weight loss trial results; Eli Lilly dips7 MarElliot SmithBy Elliot Smithmore_vert
FortuneNovo Nordisk's Wegovy and Ozempic boom saved Denmark's GDP from a no-growth 20235 MarNiclas RolanderBy Niclas Rolandermore_vert
Cleanroom TechnologyNNE delivers conceptual and basic design for Novo Nordisk expansion11 Janmore_vert
BBC.comWegovy, the 'Viagra' of weight-loss drugs flying off the shelves11 FebAdrienne MurrayBy Adrienne Murraymore_vert